辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PFE 辉瑞

交易中 12-17 15:33:29 EST

25.07

-0.46

-1.80%

最高25.49	最低25.06	成交量4,326万
今开25.42	昨收25.53	日振幅1.66%
总市值1,425亿	流通市值1,423亿	总股本56.86亿
成交额10.90亿	换手率0.76%	流通股本56.76亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PFE","market":"US","secType":"STK","nameCN":"辉瑞","latestPrice":25.07,"timestamp":1766003608346,"preClose":25.53,"halted":0,"volume":43261775,"delay":0,"floatShares":5675908374,"shares":5685707552,"eps":1.726245,"marketStatus":"交易中","change":-0.46,"latestTime":"12-17 15:33:29 EST","open":25.42,"high":25.485,"low":25.06,"amount":1089639691.3851001,"amplitude":0.016647,"askPrice":25.08,"askSize":9881,"bidPrice":25.07,"bidSize":6203,"shortable":3,"etf":0,"ttmEps":1.726245,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1766005200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":-819144000000,"exchange":"NYSE","adjPreClose":25.53,"dividendRate":0.06781,"preHourTrading":{"tag":"盘前","latestPrice":25.27,"preClose":25.53,"latestTime":"09:29 EST","volume":781369,"amount":19927456.76294,"timestamp":1765981799892},"postHourTrading":{"tag":"盘后","latestPrice":25.43,"preClose":25.53,"latestTime":"19:59 EST","volume":3562091,"amount":90923699.6793,"timestamp":1765933188725},"volumeRatio":0.765234,"optionData":{"bulkOrders":[{"symbol":"PFE","call":true,"expireDate":1768539600000,"strike":"26.0","timestamp":1765998348539,"price":0.36,"volume":30200,"amount":1087200,"type":"+"},{"symbol":"PFE","call":false,"expireDate":1768539600000,"strike":"26.0","timestamp":1765998348537,"price":1.13,"volume":30200,"amount":3412600,"type":"+"}]},"impliedVol":0.2616,"impliedVolPercentile":0.168},"requestUrl":"/m/hq/s/PFE","defaultTab":"news","newsList":[{"id":"1122571047","title":"辉瑞：Padcev联合Keytruda显著提高肌肉侵袭性膀胱癌患者的生存率，无论是否符合顺铂治疗条件","url":"https://stock-news.laohu8.com/highlight/detail?id=1122571047","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122571047?lang=zh_cn&edition=full","pubTime":"2025-12-17 19:46","pubTimestamp":1765971998,"startTime":"0","endTime":"0","summary":"辉瑞：Padcev联合Keytruda显著提高肌肉侵袭性膀胱癌患者的生存率，无论是否符合顺铂治疗条件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225771236.USD","LU0234572021.USD","LU1057294990.SGD","IE0002270589.USD","LU0289739699.SGD","BK4007","LU0306807586.USD","BK4533","PFE","BK4534","IE000M9KFDE8.USD","LU1883839398.USD","IE00BLSP4239.USD","LU0456855351.SGD","LU0321505868.SGD","LU1894683348.USD","BK4585","IE00B19Z3581.USD","LU1066053197.SGD","SG9999013999.USD","BK4588","LU0170899867.USD","SG9999001176.SGD","BK4592","LU0306806265.USD","LU1894683264.USD","SGXZ57979304.SGD","SG9999002224.SGD","IE00BLSP4452.SGD","BK4581","BK4599","LU0058720904.USD","LU1023059063.AUD","BK4550","LU1066051498.USD","LU0985481810.HKD","SG9999011175.SGD","SG9999003800.SGD","SG9999001176.USD","IE00BBT3K403.USD","BK4568","LU0868494617.USD","LU0321505439.SGD","IE00B19Z3B42.SGD","LU0122379950.USD","LU0225284248.USD","SG9999002232.USD"],"gpt_icon":0},{"id":"1152170542","title":"辉瑞：新辅助Padcev联合Pembrolizumab与新辅助化疗相比达到了病理完全缓解率","url":"https://stock-news.laohu8.com/highlight/detail?id=1152170542","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152170542?lang=zh_cn&edition=full","pubTime":"2025-12-17 19:46","pubTimestamp":1765971966,"startTime":"0","endTime":"0","summary":"辉瑞：新辅助Padcev联合Pembrolizumab与新辅助化疗相比达到了病理完全缓解率","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","SG9999002224.SGD","LU0321505868.SGD","LU0225771236.USD","LU0234572021.USD","SG9999003800.SGD","IE0002270589.USD","LU0170899867.USD","BK4599","LU0122379950.USD","LU0289739699.SGD","LU0456855351.SGD","BK4550","LU1066053197.SGD","BK4585","SG9999011175.SGD","LU0321505439.SGD","BK4007","LU0306806265.USD","LU1057294990.SGD","SG9999001176.USD","LU0225284248.USD","SG9999002232.USD","BK4581","BK4588","LU1894683264.USD","IE000M9KFDE8.USD","PFE","SG9999001176.SGD","IE00B19Z3B42.SGD","LU1894683348.USD","IE00BLSP4239.USD","BK4534","SG9999013999.USD","LU1883839398.USD","LU0985481810.HKD","LU0868494617.USD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU1023059063.AUD","LU1066051498.USD","BK4533","LU0306807586.USD","IE00BLSP4452.SGD","LU0058720904.USD","IE00B19Z3581.USD","BK4592"],"gpt_icon":0},{"id":"1147280157","title":"辉瑞：Padcev加Pembrolizumab的安全性资料与已知治疗方案的资料一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1147280157","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147280157?lang=zh_cn&edition=full","pubTime":"2025-12-17 19:45","pubTimestamp":1765971954,"startTime":"0","endTime":"0","summary":"辉瑞：Padcev加Pembrolizumab的安全性资料与已知治疗方案的资料一致","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","SG9999011175.SGD","LU0456855351.SGD","LU0321505868.SGD","LU0058720904.USD","SGXZ57979304.SGD","SG9999001176.USD","LU0225771236.USD","BK4599","BK4588","BK4592","LU0306807586.USD","LU0321505439.SGD","LU1066051498.USD","LU0122379950.USD","LU1883839398.USD","LU0306806265.USD","LU1023059063.AUD","IE00B19Z3581.USD","IE00BLSP4239.USD","SG9999002224.SGD","SG9999003800.SGD","BK4550","BK4581","LU0225284248.USD","LU1894683264.USD","SG9999001176.SGD","IE0002270589.USD","LU1057294990.SGD","IE00BBT3K403.USD","LU0289739699.SGD","SG9999013999.USD","IE00BLSP4452.SGD","LU0170899867.USD","LU0234572021.USD","SG9999002232.USD","BK4533","PFE","IE000M9KFDE8.USD","BK4534","LU0985481810.HKD","BK4007","BK4568","LU0868494617.USD","LU1894683348.USD","BK4585","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"1116380076","title":"辉瑞：第三阶段EV-304试验显示事件无进展生存期和总生存期的临床意义和统计学显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1116380076","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116380076?lang=zh_cn&edition=full","pubTime":"2025-12-17 19:45","pubTimestamp":1765971953,"startTime":"0","endTime":"0","summary":"辉瑞：第三阶段EV-304试验显示事件无进展生存期和总生存期的临床意义和统计学显著改善","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","IE00B19Z3B42.SGD","LU0868494617.USD","LU1894683348.USD","SGXZ57979304.SGD","BK4592","LU1023059063.AUD","LU0456855351.SGD","PFE","BK4585","LU0321505868.SGD","LU1057294990.SGD","BK4599","LU0985481810.HKD","LU0122379950.USD","IE000M9KFDE8.USD","IE00BBT3K403.USD","LU0234572021.USD","SG9999003800.SGD","IE00B19Z3581.USD","BK4588","LU0225284248.USD","SG9999001176.SGD","LU0321505439.SGD","BK4550","LU0170899867.USD","SG9999011175.SGD","SG9999001176.USD","IE0002270589.USD","BK4007","BK4534","LU0306806265.USD","LU1894683264.USD","BK4581","IE00BLSP4239.USD","LU1066051498.USD","BK4533","SG9999002232.USD","SG9999013999.USD","LU1066053197.SGD","LU0289739699.SGD","IE00BLSP4452.SGD","BK4568","LU1883839398.USD","SG9999002224.SGD","LU0306807586.USD","LU0225771236.USD"],"gpt_icon":0},{"id":"2592351709","title":"辉瑞股价下跌5.2%，创4月10日以来最大盘中跌幅","url":"https://stock-news.laohu8.com/highlight/detail?id=2592351709","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592351709?lang=zh_cn&edition=full","pubTime":"2025-12-16 23:50","pubTimestamp":1765900212,"startTime":"0","endTime":"0","summary":"辉瑞股价下跌5.2%，创4月10日以来最大盘中跌幅","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512163593356812.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163593356812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0058720904.USD","IE00B19Z3B42.SGD","LU0868494617.USD","LU1894683348.USD","SGXZ57979304.SGD","BK4592","LU1023059063.AUD","LU0456855351.SGD","PFE","BK4585","LU0321505868.SGD","LU1057294990.SGD","BK4599","LU0985481810.HKD","LU0122379950.USD","IE000M9KFDE8.USD","IE00BBT3K403.USD","LU0234572021.USD","SG9999003800.SGD","IE00B19Z3581.USD","BK4588","LU0225284248.USD","SG9999001176.SGD","LU0321505439.SGD","BK4550","LU0170899867.USD","SG9999011175.SGD","SG9999001176.USD","IE0002270589.USD","BK4007","BK4534","LU0306806265.USD","LU1894683264.USD","BK4581","IE00BLSP4239.USD","LU1066051498.USD","BK4533","SG9999002232.USD","SG9999013999.USD","LU1066053197.SGD","LU0289739699.SGD","IE00BLSP4452.SGD","BK4568","LU1883839398.USD","SG9999002224.SGD","LU0306807586.USD","LU0225771236.USD"],"gpt_icon":0},{"id":"2591935614","title":"辉瑞大跌5.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591935614","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591935614?lang=zh_cn&edition=full","pubTime":"2025-12-16 23:44","pubTimestamp":1765899899,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4533","BK4599","LU0321505439.SGD","IE00BLSP4239.USD","BK4585","PFE","LU0306807586.USD","SG9999013999.USD","IE00BLSP4452.SGD","LU0306806265.USD","LU0225771236.USD","BK4007","LU1023059063.AUD","LU1057294990.SGD","BK4568","LU1894683264.USD","LU0868494617.USD","BK4592","LU0985481810.HKD","BK4550","IE00BBT3K403.USD","LU0234572021.USD","SGXZ57979304.SGD","SG9999011175.SGD","LU1066053197.SGD","LU0321505868.SGD","IE0002270589.USD","SG9999001176.USD","IE00B19Z3581.USD","SG9999001176.SGD","SG9999002232.USD","SG9999003800.SGD","SG9999002224.SGD","BK4588","LU0122379950.USD","LU1883839398.USD","BK4581","LU0289739699.SGD","BK4534","IE000M9KFDE8.USD","LU0225284248.USD","LU1894683348.USD","LU0456855351.SGD","LU0170899867.USD","LU1066051498.USD","IE00B19Z3B42.SGD","LU0058720904.USD"],"gpt_icon":0},{"id":"2591935357","title":"辉瑞预计将再投资5亿美元，以提升研发生产力","url":"https://stock-news.laohu8.com/highlight/detail?id=2591935357","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591935357?lang=zh_cn&edition=full","pubTime":"2025-12-16 20:00","pubTimestamp":1765886423,"startTime":"0","endTime":"0","summary":"辉瑞预计将再投资5亿美元，以提升研发生产力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216201800a6a98afb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216201800a6a98afb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4592","LU1066051498.USD","LU1894683348.USD","LU0289739699.SGD","LU1057294990.SGD","IE0002270589.USD","SG9999002232.USD","BK4599","IE000M9KFDE8.USD","LU0170899867.USD","SG9999002224.SGD","BK4588","IE00B19Z3B42.SGD","BK4550","SG9999001176.USD","LU1883839398.USD","BK4534","LU0306807586.USD","IE00B19Z3581.USD","LU0225771236.USD","LU0122379950.USD","BK4007","LU0456855351.SGD","IE00BLSP4452.SGD","LU1066053197.SGD","SGXZ57979304.SGD","LU1894683264.USD","LU1023059063.AUD","LU0234572021.USD","LU0306806265.USD","LU0868494617.USD","BK4568","LU0321505868.SGD","SG9999001176.SGD","SG9999013999.USD","IE00BLSP4239.USD","BK4585","LU0058720904.USD","LU0321505439.SGD","LU0985481810.HKD","SG9999003800.SGD","BK4533","LU0225284248.USD","SG9999011175.SGD","PFE","IE00BBT3K403.USD","BK4581"],"gpt_icon":0},{"id":"1149840039","title":"辉瑞更新业绩指引，预计2026年盈利将低于市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1149840039","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149840039?lang=zh_cn&edition=full","pubTime":"2025-12-16 19:50","pubTimestamp":1765885816,"startTime":"0","endTime":"0","summary":"12月16日，$辉瑞(PFE)$盘前跌近2%！预计2025年营收约为620亿美元，此前预计为610亿至640亿美元。预计2026年营收为595亿美元至625亿美元。预计2026年调整后EPS为2.80美元至3.00美元。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"639473b3c472e9213a020288fd70a32f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"辉瑞预计2025年营收约620亿美元，此前预计为610亿至640亿","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFE"],"gpt_icon":0},{"id":"2591983074","title":"围绕2030年发展，多家国内外药企发布相关战略及愿景！","url":"https://stock-news.laohu8.com/highlight/detail?id=2591983074","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591983074?lang=zh_cn&edition=full","pubTime":"2025-12-16 13:11","pubTimestamp":1765861889,"startTime":"0","endTime":"0","summary":"2025年，有多家国内外药企围绕2030年发展，发布了相关战略或明确核心愿景，涵盖创新研发、商业化目标、全球化布局等多个维度。云顶新耀近日，云顶新耀发布2030年发展战略，系统规划了未来五年的发展路径。复星医药复星医药在2030年前设定了多项发展目标，主要聚焦于创新药研发、国际化战略、市场地位提升及业务结构优化等方面。在去年其提出过“中国2030战略”，当前该战略首期答卷已在第八届进博会上披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216131228a450e749&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216131228a450e749&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","01952","PFE","BK1574","06978"],"gpt_icon":0},{"id":"2591935317","title":"1天两笔交易，超26亿美元！制药巨头抢滩自免赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2591935317","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591935317?lang=zh_cn&edition=full","pubTime":"2025-12-16 12:07","pubTimestamp":1765858063,"startTime":"0","endTime":"0","summary":"临近年关，自身免疫领域迎来两笔重磅交易。12月15日，辉瑞与赛诺菲两大制药巨头相继出手，分别与Adaptive Biotechnologies及Dren Bio达成合作，潜在交易总额超26亿美元，为2025年的BD市场画上浓墨重彩的一笔。该交易包含预付款及高达8.9亿美元的里程碑金额，双方还达成了一项独立的TCR数据授权合作。今年8月，其与基因泰克的个性化TCR细胞疗法合作宣告终止。Dren将获得1亿美元预付款，并有机会获取高达17亿美元的里程碑付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216133718a6a810a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216133718a6a810a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BLSP4239.USD","LU1057294990.SGD","BK4585","BK4588","BK4592","SG9999001176.SGD","SG9999013999.USD","LU0321505868.SGD","LU1066051498.USD","SG9999011175.SGD","LU0234572021.USD","IE00B19Z3B42.SGD","BK4534","LU1023059063.AUD","LU0225284248.USD","IE00BLSP4452.SGD","LU0289739699.SGD","SG9999001176.USD","SG9999002224.SGD","LU0868494617.USD","BK4550","LU0306806265.USD","LU0058720904.USD","LU0456855351.SGD","BK4581","LU0306807586.USD","LU1883839398.USD","SGXZ57979304.SGD","IE0002270589.USD","BK4007","LU0321505439.SGD","SG9999003800.SGD","LU0985481810.HKD","LU0170899867.USD","BK4568","IE00B19Z3581.USD","IE00BBT3K403.USD","BK4533","LU1894683348.USD","LU1066053197.SGD","BK4599","LU1894683264.USD","LU0225771236.USD","LU0122379950.USD","PFE","SG9999002232.USD","SNY","IE000M9KFDE8.USD"],"gpt_icon":1},{"id":"2591667541","title":"突发！辉瑞21亿美元买走中国减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=2591667541","media":"药闻社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591667541?lang=zh_cn&edition=full","pubTime":"2025-12-14 23:22","pubTimestamp":1765725731,"startTime":"0","endTime":"0","summary":"最近减肥药赛道可真热闹，上个月辉瑞刚砸下100亿美元收购Metsera，如今又巨资锁定中国小分子减肥药。在今年中国创新药飞涨的行情中，辉瑞接洽国内药企洽谈减肥药BD出海的小作文层出不穷。从今年的数据看，礼来的GLP-1双靶点药物替尔泊肽今年前三季度销售额高达186.8亿美元，全年有望突破350亿美元，拿下GLP-1RA减肥药57%的市场份额。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214232543a6a193f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214232543a6a193f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0234572021.USD","LU0868494617.USD","LU0456855351.SGD","LU1894683264.USD","BK4533","LU0321505868.SGD","PFE","SG9999001176.USD","IE00BLSP4452.SGD","LU1023059063.AUD","SG9999002224.SGD","SG9999013999.USD","BK4588","BK4568","LU1894683348.USD","LU1883839398.USD","IE0002270589.USD","IE00BBT3K403.USD","LU0225771236.USD","LU0321505439.SGD","BK4592","LU0289739699.SGD","BK4581","BK4599","SG9999011175.SGD","IE000M9KFDE8.USD","BK4534","LU0058720904.USD","SG9999002232.USD","SG9999001176.SGD","LU1057294990.SGD","IE00B19Z3B42.SGD","LU0985481810.HKD","BK4007","LU1066051498.USD","IE00BLSP4239.USD","LU0225284248.USD","LU1066053197.SGD","BK4585","LU0306807586.USD","LU0122379950.USD","LU0306806265.USD","SG9999003800.SGD","BK4550","LU0170899867.USD","IE00B19Z3581.USD","SGXZ57979304.SGD"],"gpt_icon":1},{"id":"2591966754","title":"中国药企口服 GLP-1 超 20 亿美元授权辉瑞；正大天晴全球首个 CDK2/4/6 抑制剂获批上市｜Insight 新药周报","url":"https://stock-news.laohu8.com/highlight/detail?id=2591966754","media":"丁香园 Insight 数据库","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591966754?lang=zh_cn&edition=full","pubTime":"2025-12-14 13:48","pubTimestamp":1765691311,"startTime":"0","endTime":"0","summary":"伊奈利珠单抗本次gMG 新适应症的获批主要基于其全球关键性 Ⅲ 期试验 MINT 的积极结果。其中 MuSK+组随访 26 周，AChR+组随访 52 周。该申请此前已获 FDA 优先审查资格。临床试验动态1、德睿智药：口服小分子 GLP-1 首次启动 III 期临床12 月 10 日，德睿智药在 ClinicalTrials 官网登记了一项MDR-001 针对肥胖或超重受试者的 III 期临床。公开资料显示，这是该药启动的首个 III 期。该临床试验的目标是确定口服药物 MDR-001 是否能够改善超重或肥胖成年参与者的体重管理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214135346a4493885&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214135346a4493885&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PFE","IE00BLSP4239.USD","SG9999001176.SGD","BK4581","IE000M9KFDE8.USD","SG9999001176.USD","LU0868494617.USD","IE00BBT3K403.USD","LU1894683264.USD","SG9999011175.SGD","SG9999002232.USD","LU1066051498.USD","GLP","BK4007","BK4585","LU0456855351.SGD","SG9999003800.SGD","IE00BLSP4452.SGD","LU0985481810.HKD","IE00B19Z3B42.SGD","LU0225771236.USD","BK4568","IE0002270589.USD","LU0321505439.SGD","SGXZ57979304.SGD","BK4599","LU0321505868.SGD","SG9999013999.USD","LU1066053197.SGD","SG9999002224.SGD","LU0289739699.SGD","LU0225284248.USD","LU1057294990.SGD","BK4533","BK4534","BK4588","LU1023059063.AUD","LU0058720904.USD","LU0234572021.USD","LU0170899867.USD","BK4590","IE00B19Z3581.USD","LU1894683348.USD","LU0306806265.USD","LU1883839398.USD","LU0122379950.USD","BK4592","BK4144","LU0306807586.USD","BK4550"],"gpt_icon":1},{"id":"2590097795","title":"2025年药企全球裁员潮上10000人，辉瑞也宣布裁200多人！","url":"https://stock-news.laohu8.com/highlight/detail?id=2590097795","media":"药械VIP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590097795?lang=zh_cn&edition=full","pubTime":"2025-12-12 19:34","pubTimestamp":1765539287,"startTime":"0","endTime":"0","summary":"2025年12月10日，辉瑞将在瑞士裁减200多个岗位，将当地员工数量从约300人缩减至约70人，此举是其多年成本削减计划及瑞士业务整体调整的一部分。报道称在拉尔接手后，其业务职责范围有所收窄。回溯今年，5月裁员143人，7月裁员87人，加上此次，仅在南旧金山的裁员总数已达348人。更令人震惊的是，自2024年4月以来，基因泰克已裁员800多人。诺德宣布：减肥药巨头诺和诺德宣布，将在全球范围内裁员约9000人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212204350a69c06a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212204350a69c06a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1066051498.USD","LU0170899867.USD","LU0225284248.USD","SG9999002224.SGD","LU1057294990.SGD","LU1066053197.SGD","IE0002270589.USD","BK4588","BK4599","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4568","IE00BKVL7J92.USD","LU0321505439.SGD","IE00BLSP4239.USD","IE00BLSP4452.SGD","BK4532","LU1894683264.USD","BK4581","LU0234572021.USD","LU1093756325.SGD","SGXZ57979304.SGD","NVO","LU1093756168.USD","LU0289739699.SGD","IE00BBT3K403.USD","SG9999003800.SGD","BK4533","LU0058720904.USD","LU0225771236.USD","SG9999011175.SGD","PFE","BK4550","BK4534","IE00B19Z3581.USD","SG9999001176.SGD","LU1023059063.AUD","LU1883839398.USD","LU1894683348.USD","LU0456855351.SGD","SG9999002232.USD","LU0868494617.USD","SG9999013999.USD","IE000M9KFDE8.USD","SG9999001176.USD","LU0985481810.HKD","LU0306806265.USD","LU0306807586.USD","BK4592","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2590725265","title":"巨头卷向“三重靶点”减重药，国内价格战即将打响","url":"https://stock-news.laohu8.com/highlight/detail?id=2590725265","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590725265?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:36","pubTimestamp":1765532204,"startTime":"0","endTime":"0","summary":"巨头押注“三重靶点”减重药当地时间12月11日，礼来发布数据称，该公司在研的新一代GLP-1类减重药retatrutide在一项后期临床试验中帮助患者减重近29%。目前礼来的替尔泊肽不同剂量可帮助患者减重15%至21%。届时，礼来与竞争对手诺和诺德的竞争将延伸至口服减重药领域。与糖尿病药物相比，用于减重适应症的治疗药物的定价通常较高。而随着大量仿制药的上市，2026年，一场GLP-1药物的价格战也即将打响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212173720a69ba0b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212173720a69ba0b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0234572021.USD","01801","LU0456855351.SGD","LU1894683264.USD","NVO","LU0321505868.SGD","PFE","BK4160","IE00BLSP4452.SGD","SG9999001176.USD","SG9999002224.SGD","LU1093756325.SGD","SG9999013999.USD","BK4588","BK4568","LU1894683348.USD","LU1883839398.USD","IE0002270589.USD","IE00BBT3K403.USD","LU0225771236.USD","LU0321505439.SGD","BK4592","LU0289739699.SGD","BK4581","BK4599","LU1093756168.USD","SG9999011175.SGD","IE000M9KFDE8.USD","BK4534","LU0058720904.USD","SG9999002232.USD","SG9999001176.SGD","LU1057294990.SGD","03933","IE00B19Z3B42.SGD","LU0985481810.HKD","BK4007","LU1066051498.USD","LU1066053197.SGD","IE00BZ1G4Q59.USD","BK4585","LU0306807586.USD","LU0122379950.USD","GIPR","SG9999003800.SGD","BK4532","BK4550","IE00BKVL7J92.USD","LU0170899867.USD","IE00B19Z3581.USD","SGXZ57979304.SGD","LU0154236417.USD"],"gpt_icon":1},{"id":"2590552264","title":"辉瑞拟在瑞士裁员逾200人","url":"https://stock-news.laohu8.com/highlight/detail?id=2590552264","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590552264?lang=zh_cn&edition=full","pubTime":"2025-12-11 09:06","pubTimestamp":1765415200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff5064eb621567456e415b4b163d2eed","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0170899867.USD","LU1057294990.SGD","BK4599","LU1066053197.SGD","SG9999003800.SGD","LU1894683348.USD","SG9999001176.USD","LU0321505439.SGD","IE000M9KFDE8.USD","IE00BBT3K403.USD","LU0868494617.USD","LU0985481810.HKD","LU0321505868.SGD","BK4534","BK4533","LU0456855351.SGD","BK4592","IE00BLSP4452.SGD","LU0225771236.USD","BK4585","BK4550","BK4588","PFE","SG9999002232.USD","LU1023059063.AUD","LU0306807586.USD","SGXZ57979304.SGD","LU0058720904.USD","LU0306806265.USD","BK4007","LU0289739699.SGD","SG9999001176.SGD","SG9999011175.SGD","LU1883839398.USD","IE00B19Z3B42.SGD","LU0225284248.USD","BK4568","LU0122379950.USD","SG9999013999.USD","SG9999002224.SGD","IE00BLSP4239.USD","LU0234572021.USD","LU1066051498.USD","LU1894683264.USD","IE0002270589.USD","IE00B19Z3581.USD","BK4581"],"gpt_icon":0},{"id":"1116429656","title":"辉瑞将在年底前将瑞士员工人数从300减少至约70","url":"https://stock-news.laohu8.com/highlight/detail?id=1116429656","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116429656?lang=zh_cn&edition=full","pubTime":"2025-12-11 00:31","pubTimestamp":1765384261,"startTime":"0","endTime":"0","summary":"辉瑞将在年底前将瑞士的员工人数从300减少至约70。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff5064eb621567456e415b4b163d2eed","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1066051498.USD","LU0122379950.USD","LU0170899867.USD","LU0225284248.USD","SG9999002224.SGD","LU1057294990.SGD","LU1066053197.SGD","IE0002270589.USD","BK4588","BK4599","BK4568","LU0321505439.SGD","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU1894683264.USD","BK4581","BK4585","LU0234572021.USD","SGXZ57979304.SGD","LU0289739699.SGD","IE00BBT3K403.USD","SG9999003800.SGD","BK4533","LU0058720904.USD","LU0225771236.USD","SG9999011175.SGD","PFE","BK4550","BK4534","IE00B19Z3581.USD","SG9999001176.SGD","LU1023059063.AUD","LU1883839398.USD","LU1894683348.USD","LU0456855351.SGD","SG9999002232.USD","LU0868494617.USD","LU0321505868.SGD","IE000M9KFDE8.USD","SG9999001176.USD","SG9999013999.USD","LU0985481810.HKD","LU0306806265.USD","LU0306807586.USD","BK4592","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"1197740374","title":"Tukysa加入一线维持治疗使Her2+转移性乳腺癌患者的中位无进展生存期延长超过8个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1197740374","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197740374?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:19","pubTimestamp":1765372789,"startTime":"0","endTime":"0","summary":"Tukysa加入一线维持治疗使Her2+转移性乳腺癌患者的中位无进展生存期延长超过8个月。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456855351.SGD","BK4550","BK4599","IE00B19Z3B42.SGD","LU0868494617.USD","LU1883839398.USD","BK4007","PFE","SG9999003800.SGD","LU1894683348.USD","LU0321505868.SGD","LU0058720904.USD","IE0002270589.USD","LU1057294990.SGD","IE00B19Z3581.USD","LU1066051498.USD","SG9999001176.USD","BK4588","BK4568","IE00BBT3K403.USD","LU0225284248.USD","BK4534","BK4533","LU0321505439.SGD","SG9999011175.SGD","LU0234572021.USD","LU1066053197.SGD","BK4592","LU0122379950.USD","BK4585","IE00BLSP4239.USD","IE000M9KFDE8.USD","LU0225771236.USD","SGXZ57979304.SGD","LU0985481810.HKD","SG9999013999.USD","LU1023059063.AUD","SG9999002232.USD","LU1894683264.USD","LU0170899867.USD","SG9999001176.SGD","SG9999002224.SGD","LU0306806265.USD","IE00BLSP4452.SGD","BK4581","LU0289739699.SGD","LU0306807586.USD"],"gpt_icon":0},{"id":"1109987002","title":"辉瑞：Tukysa、曲妥珠单抗与珀妥珠单抗联用显示可控的安全性作为一线维持治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1109987002","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109987002?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:19","pubTimestamp":1765372745,"startTime":"0","endTime":"0","summary":"辉瑞：Tukysa、曲妥珠单抗与珀妥珠单抗联用显示可控的安全性作为一线维持治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683264.USD","SG9999003800.SGD","SG9999002232.USD","IE000M9KFDE8.USD","LU1057294990.SGD","LU1066051498.USD","PFE","BK4533","BK4550","IE00BLSP4239.USD","LU0985481810.HKD","LU0170899867.USD","IE00B19Z3581.USD","BK4599","BK4568","SGXZ57979304.SGD","LU0456855351.SGD","SG9999013999.USD","LU0234572021.USD","LU1894683348.USD","BK4581","LU1066053197.SGD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","SG9999001176.USD","BK4585","LU0289739699.SGD","LU0321505868.SGD","BK4007","IE00BBT3K403.USD","LU1023059063.AUD","LU0868494617.USD","LU0225771236.USD","SG9999011175.SGD","LU0321505439.SGD","IE0002270589.USD","BK4592","SG9999002224.SGD","BK4588","LU0058720904.USD","LU0122379950.USD","LU0225284248.USD","SG9999001176.SGD","LU0306806265.USD","LU0306807586.USD","BK4534","LU1883839398.USD"],"gpt_icon":0},{"id":"1145215489","title":"辉瑞：Tukysa、曲妥珠单抗与帕妥珠单抗联合使用在三期研究中相比曲妥珠单抗与帕妥珠单抗单独使用将疾病进展/死亡的风险降低了36%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145215489","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145215489?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:18","pubTimestamp":1765372700,"startTime":"0","endTime":"0","summary":"辉瑞：Tukysa、曲妥珠单抗与帕妥珠单抗联合使用在三期研究中相比曲妥珠单抗与帕妥珠单抗单独使用将疾病进展/死亡的风险降低了36%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","BK4581","LU1883839398.USD","LU0225284248.USD","LU1057294990.SGD","LU0321505439.SGD","LU0225771236.USD","LU0306806265.USD","LU0456855351.SGD","LU0170899867.USD","SG9999002224.SGD","PFE","BK4007","SGXZ57979304.SGD","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU0321505868.SGD","BK4550","LU1066051498.USD","LU1894683264.USD","BK4533","LU0289739699.SGD","IE000M9KFDE8.USD","LU1894683348.USD","SG9999011175.SGD","BK4592","IE00BBT3K403.USD","LU0058720904.USD","LU0234572021.USD","SG9999013999.USD","SG9999002232.USD","BK4599","IE0002270589.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","IE00B19Z3581.USD","BK4588","SG9999001176.SGD","SG9999003800.SGD","BK4585","SG9999001176.USD","LU0122379950.USD","LU0985481810.HKD","LU1066053197.SGD","BK4534","BK4568","LU0868494617.USD"],"gpt_icon":0},{"id":"1172700752","title":"辉瑞：关键次要终点整体生存率在分析时未成熟，但与Tukysa相比显示出改善的数值趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=1172700752","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172700752?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:16","pubTimestamp":1765372611,"startTime":"0","endTime":"0","summary":"辉瑞：关键次要终点整体生存率在分析时未成熟，但与Tukysa相比显示出改善的数值趋势","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4533","LU1894683264.USD","LU0868494617.USD","SG9999002224.SGD","IE00BLSP4452.SGD","BK4588","BK4534","IE0002270589.USD","IE00BLSP4239.USD","LU1023059063.AUD","IE00B19Z3581.USD","LU0289739699.SGD","LU0234572021.USD","SG9999001176.USD","SG9999002232.USD","LU0985481810.HKD","LU0306807586.USD","IE00B19Z3B42.SGD","BK4568","BK4599","LU1066051498.USD","LU1894683348.USD","LU0170899867.USD","BK4550","LU0306806265.USD","BK4592","LU0321505868.SGD","LU1883839398.USD","SG9999011175.SGD","SGXZ57979304.SGD","SG9999001176.SGD","LU1066053197.SGD","LU0225771236.USD","SG9999003800.SGD","IE00BBT3K403.USD","BK4581","LU0321505439.SGD","LU0456855351.SGD","BK4585","SG9999013999.USD","LU0122379950.USD","IE000M9KFDE8.USD","PFE","LU0058720904.USD","LU0225284248.USD","LU1057294990.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pfizer.com","stockEarnings":[{"period":"1week","weight":0.0079},{"period":"1month","weight":0.0188},{"period":"3month","weight":0.0615},{"period":"6month","weight":0.0691},{"period":"1year","weight":0.0111},{"period":"ytd","weight":-0.0377}],"compareEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":0.0103},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.1363},{"period":"1year","weight":0.1188},{"period":"ytd","weight":0.1583}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源，通过发现、开发、制造和分销保健产品（包括创新药物和疫苗），为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作，致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作，支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.001224},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.007083},{"month":3,"riseRate":0.6,"avgChangeRate":0.014714},{"month":4,"riseRate":0.586957,"avgChangeRate":0.018253},{"month":5,"riseRate":0.5,"avgChangeRate":0.007748},{"month":6,"riseRate":0.5,"avgChangeRate":0.002798},{"month":7,"riseRate":0.478261,"avgChangeRate":0.011357},{"month":8,"riseRate":0.456522,"avgChangeRate":0.0002},{"month":9,"riseRate":0.456522,"avgChangeRate":0.004432},{"month":10,"riseRate":0.630435,"avgChangeRate":0.013042},{"month":11,"riseRate":0.695652,"avgChangeRate":0.028255},{"month":12,"riseRate":0.5,"avgChangeRate":0.008984}],"exchange":"NYSE","name":"辉瑞","nameEN":"Pfizer"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"辉瑞,PFE,辉瑞股票,辉瑞股票老虎,辉瑞股票老虎国际,辉瑞行情,辉瑞股票行情,辉瑞股价,辉瑞股市,辉瑞股票价格,辉瑞股票交易,辉瑞股票购买,辉瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}